Skip to main content
PMC home page
Mediators of Inflammation logoLink to Mediators of Inflammation
. 2003 Feb;12(1):37–46. doi: 10.1080/0962935031000096953

Dexamethasone prevents interleukin-1beta-induced nuclear factor-kappaB activation by upregulating IkappaB-alpha synthesis, in lymphoblastic cells.

M Castro-Caldas 1, A F Mendes 1, A P Carvalho 1, C B Duarte 1, M C Lopes 1
PMCID: PMC1781587  PMID: 12745547

Abstract

AIMS: Glucocorticoids (GCs) exert some of their anti-inflammatory actions by preventing the activation of the transcription factor nuclear factor (NF)-kappaB. The GC-dependent inhibition of NF-kappaB may occur at different levels, but the mechanisms involved are still incompletely understood. In this work, we investigated whether the synthetic GC, dexamethasone (Dex), modulates the activity of NF-kappaB in the lymphoblastic CCRF-CEM cell line. We also evaluated the ability of Dex to prevent the activation of NF-kappaB in response to the potent proinflammatory cytokine, interleukin (IL)-1beta. RESULTS: Exposure of the cells to Dex (1 microM) induced the rapid degradation of IkappaB-alpha, leading to the transient translocation of the NF-kappaB family members p65 and p50 from the cytoplasm to the nucleus, as evaluated by western blot. Electrophoretic mobility shift assays revealed that, in the nucleus, these NF-kappaB proteins formed protein-DNA complexes, indicating a transient activation of NF-kappaB. Additionally, Dex also induced de novo synthesis of IkappaB-alpha, following its degradation. Finally, when the cells were exposed to Dex (1 microM) prior to stimulation with IL-1beta (20 ng/ml), Dex was efficient in preventing IL-1beta-induced NF-kappaB activation. The GC antagonist, RU 486 (10 microM), did not prevent any of the effects of Dex reported here. CONCLUSION: Our results indicate that, in CCRF-CEM cells, Dex prevents NF-kappaB activation, induced by IL-1beta, by a mechanism that involves the upregulation of IkappaB-alpha synthesis, and that depends on the early and transient activation of NF-kappaB.

Full Text

The Full Text of this article is available as a PDF (487.2 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Adcock I. M., Nasuhara Y., Stevens D. A., Barnes P. J. Ligand-induced differentiation of glucocorticoid receptor (GR) trans-repression and transactivation: preferential targetting of NF-kappaB and lack of I-kappaB involvement. Br J Pharmacol. 1999 Jun;127(4):1003–1011. doi: 10.1038/sj.bjp.0702613. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Almawi W. Y., Melemedjian O. K. Negative regulation of nuclear factor-kappaB activation and function by glucocorticoids. J Mol Endocrinol. 2002 Apr;28(2):69–78. doi: 10.1677/jme.0.0280069. [DOI] [PubMed] [Google Scholar]
  3. Auphan N., DiDonato J. A., Rosette C., Helmberg A., Karin M. Immunosuppression by glucocorticoids: inhibition of NF-kappa B activity through induction of I kappa B synthesis. Science. 1995 Oct 13;270(5234):286–290. doi: 10.1126/science.270.5234.286. [DOI] [PubMed] [Google Scholar]
  4. Baldwin A. S., Jr The NF-kappa B and I kappa B proteins: new discoveries and insights. Annu Rev Immunol. 1996;14:649–683. doi: 10.1146/annurev.immunol.14.1.649. [DOI] [PubMed] [Google Scholar]
  5. Bren G. D., Solan N. J., Miyoshi H., Pennington K. N., Pobst L. J., Paya C. V. Transcription of the RelB gene is regulated by NF-kappaB. Oncogene. 2001 Nov 22;20(53):7722–7733. doi: 10.1038/sj.onc.1204868. [DOI] [PubMed] [Google Scholar]
  6. Brostjan C., Anrather J., Csizmadia V., Stroka D., Soares M., Bach F. H., Winkler H. Glucocorticoid-mediated repression of NFkappaB activity in endothelial cells does not involve induction of IkappaBalpha synthesis. J Biol Chem. 1996 Aug 9;271(32):19612–19616. doi: 10.1074/jbc.271.32.19612. [DOI] [PubMed] [Google Scholar]
  7. Castro-Caldas M., Duarte C. B., Carvalho A. P., Lopes M. C. Fernandes. Dexamethasone induces the secretion of annexin I in immature lymphoblastic cells by a calcium-dependent mechanism. Mol Cell Biochem. 2002 Aug;237(1-2):31–38. doi: 10.1023/a:1016502120139. [DOI] [PubMed] [Google Scholar]
  8. Chen F. E., Ghosh G. Regulation of DNA binding by Rel/NF-kappaB transcription factors: structural views. Oncogene. 1999 Nov 22;18(49):6845–6852. doi: 10.1038/sj.onc.1203224. [DOI] [PubMed] [Google Scholar]
  9. De Vera M. E., Taylor B. S., Wang Q., Shapiro R. A., Billiar T. R., Geller D. A. Dexamethasone suppresses iNOS gene expression by upregulating I-kappa B alpha and inhibiting NF-kappa B. Am J Physiol. 1997 Dec;273(6 Pt 1):G1290–G1296. doi: 10.1152/ajpgi.1997.273.6.G1290. [DOI] [PubMed] [Google Scholar]
  10. Ghosh Sankar, Karin Michael. Missing pieces in the NF-kappaB puzzle. Cell. 2002 Apr;109 (Suppl):S81–S96. doi: 10.1016/s0092-8674(02)00703-1. [DOI] [PubMed] [Google Scholar]
  11. Gilmore T. D. The Rel/NF-kappaB signal transduction pathway: introduction. Oncogene. 1999 Nov 22;18(49):6842–6844. doi: 10.1038/sj.onc.1203237. [DOI] [PubMed] [Google Scholar]
  12. Gomes E. R., Cruz T., Lopes C. F., Carvalho A. P., Duarte C. B. Photosensitization of lymphoblastoid cells with phthalocyanines at different saturating incubation times. Cell Biol Toxicol. 1999;15(4):249–260. doi: 10.1023/a:1007615813184. [DOI] [PubMed] [Google Scholar]
  13. Heck S., Bender K., Kullmann M., Göttlicher M., Herrlich P., Cato A. C. I kappaB alpha-independent downregulation of NF-kappaB activity by glucocorticoid receptor. EMBO J. 1997 Aug 1;16(15):4698–4707. doi: 10.1093/emboj/16.15.4698. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Karin M. How NF-kappaB is activated: the role of the IkappaB kinase (IKK) complex. Oncogene. 1999 Nov 22;18(49):6867–6874. doi: 10.1038/sj.onc.1203219. [DOI] [PubMed] [Google Scholar]
  15. Kistler B., Rolink A., Marienfeld R., Neumann M., Wirth T. Induction of nuclear factor-kappa B during primary B cell differentiation. J Immunol. 1998 Mar 1;160(5):2308–2317. [PubMed] [Google Scholar]
  16. Mendes A. F., Carvalho A. P., Caramona M. M., Lopes M. C. Role of nitric oxide in the activation of NF-kappaB, AP-1 and NOS II expression in articular chondrocytes. Inflamm Res. 2002 Jul;51(7):369–375. doi: 10.1007/pl00000317. [DOI] [PubMed] [Google Scholar]
  17. Miyamoto S., Seufzer B. J., Shumway S. D. Novel IkappaB alpha proteolytic pathway in WEHI231 immature B cells. Mol Cell Biol. 1998 Jan;18(1):19–29. doi: 10.1128/mcb.18.1.19. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. O'Sullivan B. J., MacDonald K. P., Pettit A. R., Thomas R. RelB nuclear translocation regulates B cell MHC molecule, CD40 expression, and antigen-presenting cell function. Proc Natl Acad Sci U S A. 2000 Oct 10;97(21):11421–11426. doi: 10.1073/pnas.97.21.11421. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Ohtsuka T., Kubota A., Hirano T., Watanabe K., Yoshida H., Tsurufuji M., Iizuka Y., Konishi K., Tsurufuji S. Glucocorticoid-mediated gene suppression of rat cytokine-induced neutrophil chemoattractant CINC/gro, a member of the interleukin-8 family, through impairment of NF-kappa B activation. J Biol Chem. 1996 Jan 19;271(3):1651–1659. doi: 10.1074/jbc.271.3.1651. [DOI] [PubMed] [Google Scholar]
  20. Pahl H. L. Activators and target genes of Rel/NF-kappaB transcription factors. Oncogene. 1999 Nov 22;18(49):6853–6866. doi: 10.1038/sj.onc.1203239. [DOI] [PubMed] [Google Scholar]
  21. Phelps C. B., Sengchanthalangsy L. L., Huxford T., Ghosh G. Mechanism of I kappa B alpha binding to NF-kappa B dimers. J Biol Chem. 2000 Sep 22;275(38):29840–29846. doi: 10.1074/jbc.M004899200. [DOI] [PubMed] [Google Scholar]
  22. Quan N., He L., Lai W., Shen T., Herkenham M. Induction of IkappaBalpha mRNA expression in the brain by glucocorticoids: a negative feedback mechanism for immune-to-brain signaling. J Neurosci. 2000 Sep 1;20(17):6473–6477. doi: 10.1523/JNEUROSCI.20-17-06473.2000. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Scheinman R. I., Cogswell P. C., Lofquist A. K., Baldwin A. S., Jr Role of transcriptional activation of I kappa B alpha in mediation of immunosuppression by glucocorticoids. Science. 1995 Oct 13;270(5234):283–286. doi: 10.1126/science.270.5234.283. [DOI] [PubMed] [Google Scholar]
  24. Scheinman R. I., Gualberto A., Jewell C. M., Cidlowski J. A., Baldwin A. S., Jr Characterization of mechanisms involved in transrepression of NF-kappa B by activated glucocorticoid receptors. Mol Cell Biol. 1995 Feb;15(2):943–953. doi: 10.1128/mcb.15.2.943. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Sethna K. B., Mistry N. F., Dholakia Y., Antia N. H., Harboe M. Longitudinal trends in serum levels of mycobacterial secretory (30 kD) and cytoplasmic (65 kD) antigens during chemotherapy of pulmonary tuberculosis patients. Scand J Infect Dis. 1998;30(4):363–369. doi: 10.1080/00365549850160657. [DOI] [PubMed] [Google Scholar]
  26. Solan Nancie J., Miyoshi Hiroko, Carmona Eva M., Bren Gary D., Paya Carlos V. RelB cellular regulation and transcriptional activity are regulated by p100. J Biol Chem. 2001 Oct 30;277(2):1405–1418. doi: 10.1074/jbc.M109619200. [DOI] [PubMed] [Google Scholar]
  27. Tzen C. Y., Cox R. L., Scott R. E. Coordinate induction of I kappa B alpha and NF kappa B genes. Exp Cell Res. 1994 Mar;211(1):12–16. doi: 10.1006/excr.1994.1052. [DOI] [PubMed] [Google Scholar]
  28. Wissink S., van Heerde E. C., vand der Burg B., van der Saag P. T. A dual mechanism mediates repression of NF-kappaB activity by glucocorticoids. Mol Endocrinol. 1998 Mar;12(3):355–363. doi: 10.1210/mend.12.3.0081. [DOI] [PubMed] [Google Scholar]
  29. Yamamoto Y., Gaynor R. B. Therapeutic potential of inhibition of the NF-kappaB pathway in the treatment of inflammation and cancer. J Clin Invest. 2001 Jan;107(2):135–142. doi: 10.1172/JCI11914. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Mediators of Inflammation are provided here courtesy of Wiley

RESOURCES